News on protein analysis, clinical proteomics, biomarkers in genetics, genomics, and molecular diagnostics.
The firm is looking for outside partners to tackle test commercialization as it begins to bring its second-generation colorectal cancer assay to market.
Both published last month, the studies looked at, respectively, early-stage discovery of lung cancer markers and development of a clinical test for the disease.
The platform received 510(k) clearance from the US Food and Drug Administration for the expanded identification of mycobacteria, Nocardia, and molds.
The new version of the mass spectrometry-based system adds 144 microbial species to its database and includes new tools for sample preparation.
The company plans to develop tests for prostate cancer risk assessment, prostate cancer screening, and breast cancer screening.